Thurston, Springer, Miller, Herd & Titak, Inc. Alkermes Plc. Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $475 Million
- Q4 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 50 shares of ALKS stock, worth $1,562. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50Holding current value
$1,562% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
357Shares Held
180MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$910 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$593 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$406 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$396 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$287 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.13B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...